BerGenBio participation at upcoming healthcare investor and life sciences industry conferences
Bergen, Norway, 14 May 2018– BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.· 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)* · 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)* · 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)* · 4 June, Norne Securities Conference (Bergen, Norway)* · 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago,